RxDoctor Payments Data

Waheed Gul, MD

Gastroenterology · Chillicothe, OHNPI 1205813763

Payments from drug & device makers

$3,829in general payments, 2019–2025

Across 172 payments — averaging $22.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Johnson & Johnson$753
  • AbbVie$698
  • Takeda Pharmaceuticals U.S.A., Inc.$235
  • Gilead$194
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$139
  • plus $751 from 14 others

What the payments were for

  • Travel & lodging$74519%
  • Food & beverage$2,90676%
  • Education$1775%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,829 in reported general payments places this provider in the 55th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$114,116
Medicare patients
527
Services billed
939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide15$12,605
Mesalamine12$4,115
Mesalamine DrMesalamine16$3,617
Ursodiol18$3,293
Sucralfate26$2,992
Balsalazide Disodium14$2,761
CholestyramineCholestyramine (With Sugar)26$1,998
Omeprazole159$1,622
Lubiprostone19$1,520
Vancomycin Hcl11$1,172
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl82$1,025
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl52$767
Spironolactone32$518
Pantoprazole Sodium59$508
Esomeprazole Magnesium15$420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$698$12,60515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 657 gastroenterology providers in Ohio.

Other gastroenterology in Chillicothe

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →